Literature DB >> 30848661

Cystic Fibrosis Plasma Blunts the Immune Response to Bacterial Infection.

Xi Zhang1,2,3, Amy Pan4,5, Shuang Jia6,7, Justin E Ideozu1,2,3, Katherine Woods8, Kathleen Murkowski8, Martin J Hessner4,6,7, Pippa M Simpson4,5, Hara Levy1,2,3.   

Abstract

Cystic fibrosis (CF) is caused by mutations of the gene encoding the CF transmembrane conductance regulator. It remains unclear whether the abnormal immune response in CF involves extrinsic signals released from the external or internal environment. We sought to characterize the peripheral immune signatures in CF and its association with clinical phenotypes. Healthy peripheral blood mononuclear cells (PBMCs) were cultured with plasma from CF probands (CFPs) or healthy control subjects (HCs) followed by nCounter gene and microRNA (miRNA) profiling. A discovery cohort of 12 CFPs and 12 HCs and a validation cohort of 103 CFPs and 31 HCs (our previous microarray data [GSE71799]) were analyzed to characterize the composition of cultured immune cells and establish a miRNA‒mRNA network. Cell compositions and miRNA profiles were associated with clinical characteristics of the cohorts. Significantly differentially expressed genes and abundance of myeloid cells were downregulated in PMBCs after culture with CF plasma (P < 0.05). Top-ranked miRNAs that increased in response to CF plasma (adjusted P < 0.05) included miR-155 and miR-146a, which target many immune-related genes, such as IL-8. Pseudomonas aeruginosa infection was negatively associated with abundance of monocytes and the presence of those regulatory miRNAs. Extrinsic signals in plasma from patients with CF led to monocyte inactivation and miRNA upregulation in PBMCs. An improved understanding of the immune effects of extrinsic factors in CF holds great promise for integrating immunomodulatory cell therapies into current treatment strategies in CF.

Entities:  

Keywords:  cystic fibrosis; gene expression; immune response; microRNA; peripheral blood mononuclear cells

Mesh:

Substances:

Year:  2019        PMID: 30848661      PMCID: PMC6839930          DOI: 10.1165/rcmb.2018-0114OC

Source DB:  PubMed          Journal:  Am J Respir Cell Mol Biol        ISSN: 1044-1549            Impact factor:   6.914


  51 in total

1.  Immune responses in cystic fibrosis: are they intrinsically defective?

Authors:  Dmitry Ratner; Christian Mueller
Journal:  Am J Respir Cell Mol Biol       Date:  2012-03-08       Impact factor: 6.914

Review 2.  Lung inflammation in cystic fibrosis: pathogenesis and novel therapies.

Authors:  Barbara Dhooghe; Sabrina Noël; François Huaux; Teresinha Leal
Journal:  Clin Biochem       Date:  2013-12-29       Impact factor: 3.281

3.  Sustained inhibition of IL-6 and IL-8 expression by decoy ODN to NF-κB delivered through respirable large porous particles in LPS-stimulated cystic fibrosis bronchial cells.

Authors:  Daniela De Stefano; Francesca Ungaro; Concetta Giovino; Antonio Polimeno; Fabiana Quaglia; Rosa Carnuccio
Journal:  J Gene Med       Date:  2011-04       Impact factor: 4.565

Review 4.  MicroRNA profiling: approaches and considerations.

Authors:  Colin C Pritchard; Heather H Cheng; Muneesh Tewari
Journal:  Nat Rev Genet       Date:  2012-04-18       Impact factor: 53.242

5.  Interleukin 8 secretion from monocytes of subjects heterozygous for the deltaF508 cystic fibrosis transmembrane conductance regulator gene mutation is altered.

Authors:  Munir M Zaman; Andres Gelrud; Omer Junaidi; Meredith M Regan; Michel Warny; Julie C Shea; Ciaran Kelly; Brian P O'Sullivan; Steven D Freedman
Journal:  Clin Diagn Lab Immunol       Date:  2004-09

6.  Differential activation and functional specialization of miR-146 and miR-155 in innate immune sensing.

Authors:  Leon N Schulte; Alexander J Westermann; Jörg Vogel
Journal:  Nucleic Acids Res       Date:  2012-11-09       Impact factor: 16.971

7.  Translocated LPS might cause endotoxin tolerance in circulating monocytes of cystic fibrosis patients.

Authors:  Rosa del Campo; Eriel Martínez; Carlos del Fresno; Raquel Alenda; Vanesa Gómez-Piña; Irene Fernández-Ruíz; María Siliceo; Teresa Jurado; Victor Toledano; Francisco Arnalich; Francisco García-Río; Eduardo López-Collazo
Journal:  PLoS One       Date:  2011-12-28       Impact factor: 3.240

8.  Involvement of inflammation-related miR-155 and miR-146a in diabetic nephropathy: implications for glomerular endothelial injury.

Authors:  Youqun Huang; Yan Liu; Ling Li; Baihai Su; Lichuan Yang; Wenxin Fan; Qinghua Yin; Lijia Chen; Tianlei Cui; Jie Zhang; Yanrong Lu; Jingqiu Cheng; Ping Fu; Fang Liu
Journal:  BMC Nephrol       Date:  2014-09-02       Impact factor: 2.388

9.  Increased Expression of Plasma-Induced ABCC1 mRNA in Cystic Fibrosis.

Authors:  Justin E Ideozu; Xi Zhang; Amy Pan; Zainub Ashrafi; Katherine J Woods; Martin J Hessner; Pippa Simpson; Hara Levy
Journal:  Int J Mol Sci       Date:  2017-08-11       Impact factor: 5.923

Review 10.  Immune cell profiling in cancer: molecular approaches to cell-specific identification.

Authors:  Yasmin A Lyons; Sherry Y Wu; Willem W Overwijk; Keith A Baggerly; Anil K Sood
Journal:  NPJ Precis Oncol       Date:  2017-08-15
View more
  10 in total

1.  Strong toll-like receptor responses in cystic fibrosis patients are associated with higher lung function.

Authors:  Susanna Kosamo; Katherine B Hisert; Victoria Dmyterko; Catherine Nguyen; R Anthony Black; Tarah D Holden; Frank Radella; Pauline A Cotten; Christopher H Goss; Moira L Aitken; Mark M Wurfel
Journal:  J Cyst Fibros       Date:  2019-12-05       Impact factor: 5.482

2.  Update in Pediatrics 2020.

Authors:  Erick Forno; Steven H Abman; Jagdev Singh; Mary E Robbins; Hiran Selvadurai; Paul T Schumacker; Paul D Robinson
Journal:  Am J Respir Crit Care Med       Date:  2021-08-01       Impact factor: 30.528

Review 3.  Thrombospondin-1: A Key Protein That Induces Fibrosis in Diabetic Complications.

Authors:  Linhao Xu; Yong Zhang; Jian Chen; Yizhou Xu
Journal:  J Diabetes Res       Date:  2020-06-11       Impact factor: 4.011

4.  MiR-146a is over-expressed and controls IL-6 production in cystic fibrosis macrophages.

Authors:  Francesco R Luly; Manuella Lévêque; Valerio Licursi; Giuseppe Cimino; Corinne Martin-Chouly; Nathalie Théret; Rodolfo Negri; Luca Cavinato; Fiorentina Ascenzioni; Paola Del Porto
Journal:  Sci Rep       Date:  2019-11-07       Impact factor: 4.379

5.  Cystic Fibrosis Inflammation: Hyperinflammatory, Hypoinflammatory, or Both?

Authors:  Sean V Murphy; Carla M P Ribeiro
Journal:  Am J Respir Cell Mol Biol       Date:  2019-09       Impact factor: 6.914

6.  Transcriptome Sequencing Identifies PLAUR as an Important Player in Patients With Dermatomyositis-Associated Interstitial Lung Disease.

Authors:  Juan Chen; Ruixian Zhang; Min Xie; Chunyan Luan; Xiaolan Li
Journal:  Front Genet       Date:  2021-12-06       Impact factor: 4.599

7.  CFTR-mediated monocyte/macrophage dysfunction revealed by cystic fibrosis proband-parent comparisons.

Authors:  Xi Zhang; Camille M Moore; Laura D Harmacek; Joanne Domenico; Vittobai Rashika Rangaraj; Justin E Ideozu; Jennifer R Knapp; Katherine J Woods; Stephanie Jump; Shuang Jia; Jeremy W Prokop; Russell Bowler; Martin J Hessner; Erwin W Gelfand; Hara Levy
Journal:  JCI Insight       Date:  2022-03-22

8.  A Splice Switch in SIGIRR Causes a Defect of IL-37-Dependent Anti-Inflammatory Activity in Cystic Fibrosis Airway Epithelial Cells.

Authors:  Keiko Ueno-Shuto; Shunsuke Kamei; Megumi Hayashi; Ayami Fukuyama; Yuji Uchida; Naofumi Tokutomi; Mary Ann Suico; Hirofumi Kai; Tsuyoshi Shuto
Journal:  Int J Mol Sci       Date:  2022-07-13       Impact factor: 6.208

9.  Microarray profiling identifies extracellular circulating miRNAs dysregulated in cystic fibrosis.

Authors:  Justin E Ideozu; Xi Zhang; Vittobai Rangaraj; Susanna McColley; Hara Levy
Journal:  Sci Rep       Date:  2019-10-29       Impact factor: 4.379

10.  CFTR Modulator Therapy Enhances Peripheral Blood Monocyte Contributions to Immune Responses in People With Cystic Fibrosis.

Authors:  Katherine B Hisert; Timothy P Birkland; Kelly Q Schoenfelt; Matthew E Long; Brenda Grogan; Suzanne Carter; W Conrad Liles; Edward F McKone; Lev Becker; Anne M Manicone; Sina A Gharib
Journal:  Front Pharmacol       Date:  2020-08-13       Impact factor: 5.810

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.